Long-term prognosis of diffuse lupus nephritis

C. Ponticelli, P. Zucchelli, G. Moroni, L. Cagnoli, G. Banfi, S. Pasquali

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The follow-up of 43 patients with diffuse proliferative lupus nephritis is reported. After histological diagnosis, all patients were treated with 3 intravenous high-dose methyl-prednisolone pulses and then with low-dose oral steroids and 31 with cytotoxic drugs. Renal and extra-renal exacerbations were also treated with intravenous high-dose steroids. Patients were followed for 1 to 13 years. At 10 years the patient survival rate was 87% and the kidney survival rate was 79%. If 3 extra-renal deaths are excluded, the actuarial 10-year kidney survival rate is 91%. At present, 21 patients do not show any renal abnormalities, 13 patients have normal plasma creatinine but proteinuria, 3 patients have stable renal function impairment, 2 patients have worsening of their renal function, 1 is on regular dialysis. The other 3 patients died (from cardiac failure, cerebral hemorhage and a car accident). The incidence of flare-ups was low (0.1 episodes per year). Severe side effects were rare in this considerably series. It is concluded that the long-term prognosis of diffuse lupus nephritis is becoming considerably better. Therapy based on a short course of intravenous high-dose methylprednisolone and on a maintenance regimen with low doses of steroid and cytotoxic agents can contribute to preserving renal function while avoiding severe side effects.

Original languageEnglish
Pages (from-to)263-271
Number of pages9
JournalClinical Nephrology
Volume28
Issue number6
Publication statusPublished - 1987

Fingerprint

Lupus Nephritis
Kidney
Survival Rate
Steroids
Cytotoxins
Methylprednisolone
Prednisolone
Proteinuria
Accidents
Dialysis
Creatinine
Heart Failure
Maintenance
Incidence

ASJC Scopus subject areas

  • Nephrology

Cite this

Ponticelli, C., Zucchelli, P., Moroni, G., Cagnoli, L., Banfi, G., & Pasquali, S. (1987). Long-term prognosis of diffuse lupus nephritis. Clinical Nephrology, 28(6), 263-271.

Long-term prognosis of diffuse lupus nephritis. / Ponticelli, C.; Zucchelli, P.; Moroni, G.; Cagnoli, L.; Banfi, G.; Pasquali, S.

In: Clinical Nephrology, Vol. 28, No. 6, 1987, p. 263-271.

Research output: Contribution to journalArticle

Ponticelli, C, Zucchelli, P, Moroni, G, Cagnoli, L, Banfi, G & Pasquali, S 1987, 'Long-term prognosis of diffuse lupus nephritis', Clinical Nephrology, vol. 28, no. 6, pp. 263-271.
Ponticelli C, Zucchelli P, Moroni G, Cagnoli L, Banfi G, Pasquali S. Long-term prognosis of diffuse lupus nephritis. Clinical Nephrology. 1987;28(6):263-271.
Ponticelli, C. ; Zucchelli, P. ; Moroni, G. ; Cagnoli, L. ; Banfi, G. ; Pasquali, S. / Long-term prognosis of diffuse lupus nephritis. In: Clinical Nephrology. 1987 ; Vol. 28, No. 6. pp. 263-271.
@article{aa8510555fc64fc49c638dd859874500,
title = "Long-term prognosis of diffuse lupus nephritis",
abstract = "The follow-up of 43 patients with diffuse proliferative lupus nephritis is reported. After histological diagnosis, all patients were treated with 3 intravenous high-dose methyl-prednisolone pulses and then with low-dose oral steroids and 31 with cytotoxic drugs. Renal and extra-renal exacerbations were also treated with intravenous high-dose steroids. Patients were followed for 1 to 13 years. At 10 years the patient survival rate was 87{\%} and the kidney survival rate was 79{\%}. If 3 extra-renal deaths are excluded, the actuarial 10-year kidney survival rate is 91{\%}. At present, 21 patients do not show any renal abnormalities, 13 patients have normal plasma creatinine but proteinuria, 3 patients have stable renal function impairment, 2 patients have worsening of their renal function, 1 is on regular dialysis. The other 3 patients died (from cardiac failure, cerebral hemorhage and a car accident). The incidence of flare-ups was low (0.1 episodes per year). Severe side effects were rare in this considerably series. It is concluded that the long-term prognosis of diffuse lupus nephritis is becoming considerably better. Therapy based on a short course of intravenous high-dose methylprednisolone and on a maintenance regimen with low doses of steroid and cytotoxic agents can contribute to preserving renal function while avoiding severe side effects.",
author = "C. Ponticelli and P. Zucchelli and G. Moroni and L. Cagnoli and G. Banfi and S. Pasquali",
year = "1987",
language = "English",
volume = "28",
pages = "263--271",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "6",

}

TY - JOUR

T1 - Long-term prognosis of diffuse lupus nephritis

AU - Ponticelli, C.

AU - Zucchelli, P.

AU - Moroni, G.

AU - Cagnoli, L.

AU - Banfi, G.

AU - Pasquali, S.

PY - 1987

Y1 - 1987

N2 - The follow-up of 43 patients with diffuse proliferative lupus nephritis is reported. After histological diagnosis, all patients were treated with 3 intravenous high-dose methyl-prednisolone pulses and then with low-dose oral steroids and 31 with cytotoxic drugs. Renal and extra-renal exacerbations were also treated with intravenous high-dose steroids. Patients were followed for 1 to 13 years. At 10 years the patient survival rate was 87% and the kidney survival rate was 79%. If 3 extra-renal deaths are excluded, the actuarial 10-year kidney survival rate is 91%. At present, 21 patients do not show any renal abnormalities, 13 patients have normal plasma creatinine but proteinuria, 3 patients have stable renal function impairment, 2 patients have worsening of their renal function, 1 is on regular dialysis. The other 3 patients died (from cardiac failure, cerebral hemorhage and a car accident). The incidence of flare-ups was low (0.1 episodes per year). Severe side effects were rare in this considerably series. It is concluded that the long-term prognosis of diffuse lupus nephritis is becoming considerably better. Therapy based on a short course of intravenous high-dose methylprednisolone and on a maintenance regimen with low doses of steroid and cytotoxic agents can contribute to preserving renal function while avoiding severe side effects.

AB - The follow-up of 43 patients with diffuse proliferative lupus nephritis is reported. After histological diagnosis, all patients were treated with 3 intravenous high-dose methyl-prednisolone pulses and then with low-dose oral steroids and 31 with cytotoxic drugs. Renal and extra-renal exacerbations were also treated with intravenous high-dose steroids. Patients were followed for 1 to 13 years. At 10 years the patient survival rate was 87% and the kidney survival rate was 79%. If 3 extra-renal deaths are excluded, the actuarial 10-year kidney survival rate is 91%. At present, 21 patients do not show any renal abnormalities, 13 patients have normal plasma creatinine but proteinuria, 3 patients have stable renal function impairment, 2 patients have worsening of their renal function, 1 is on regular dialysis. The other 3 patients died (from cardiac failure, cerebral hemorhage and a car accident). The incidence of flare-ups was low (0.1 episodes per year). Severe side effects were rare in this considerably series. It is concluded that the long-term prognosis of diffuse lupus nephritis is becoming considerably better. Therapy based on a short course of intravenous high-dose methylprednisolone and on a maintenance regimen with low doses of steroid and cytotoxic agents can contribute to preserving renal function while avoiding severe side effects.

UR - http://www.scopus.com/inward/record.url?scp=0023589311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023589311&partnerID=8YFLogxK

M3 - Article

C2 - 3327639

AN - SCOPUS:0023589311

VL - 28

SP - 263

EP - 271

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 6

ER -